Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis.
The present studies were performed to determine whether any beneficial interaction results from combination therapy with recombinant human granulocyte colony-stimulating factor (GCSF) and fluconazole in disseminated candidiasis in mice. Fluconazole extended survival and reduced tissue counts. GCSF had no direct benefit, but GCSF combined with fluconazole extended survival beyond that for fluconazole alone and reduced renal tissue counts below those for fluconazole alone. Thus, GCSF and fluconazole may be a useful combined therapy for disseminated candidiasis.
Graybill
J R
JR
University of Texas Health Science Center at San Antonio 78284, USA.
Bocanegra
R
R
Luther
M
M
D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D004195:Disease Models, Animal; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008815:Mice, Inbred Strains
D000935:Antifungal Agents; D016179:Granulocyte Colony-Stimulating Factor; D015725:Fluconazole